Endocrine Abstracts

The pubertal growth spurt involves a rapid increase then decrease in height velocity (HV), where both the timing and intensity of the spurt vary considerably between individuals. The analysis of such growth curve data is an ongoing statistical problem. Current approaches involve fitting say the Preece–Baines (PB) curve to each individual’s data, and summarising the curves by averaging the five fitted PB parameters across individuals. But this has two drawbacks: fitti...

Gonadotropin-releasing hormone analogues (GnRHa) are prescribed to adolescents with gender dysphoria under age 15 who have reached Tanner stage 2/3 to prevent progression through puberty and allow them time to consider their gender identity. The possible effects of the therapy on the pubertal growth spurt are poorly understood. A height more congruent with their identified gender is desired by transgender individuals, thus it is crucial that they are fully informed of its pote...

Background and aims: Estimating puberty using Tanner stages is usually done unconfidently by general paediatricians. Self-assessment methods are not reliable. As assessment of growth on the new UK growth charts necessitates establishing pubertal status, we have designed and evaluated a simpler non-invasive approach.Methods: The new system has three Phases– Pre-Puberty (Tanner stage 1), In-Puberty (stages 2/3) and Completing-Puberty (stages 4/5)....

The UK Turner Study examined in girls with Turner syndrome (TS) the impact on final height (FH) of Oxandrolone (Ox) and/or delayed pubertal induction (14y).Methods: Girls with TS aged 7–13y receiving GH were randomised to Ox (0.05 mg/kg per day, max. dose 2.5 mg/day) or placebo from 9y (or from enrolment if >9y). Girls requiring oestrogen were further randomised to begin oral Ethinylestradiol (E2) (Y1:2 μg/day; Y2:4 μg/day; ...

Background: Accurate genetic diagnosis is essential in disorders of sex development (DSD), guiding medical management and enabling optimal personalized care delivery.Case presentation: Two siblings (I and II) with a family history of 17β-hydroxysteroid dehydroxygenase (17β-HSD3) deficiency presented postnatally with isolated labial swelling. Karyotype was 46,XY and urinary steroid profile (USP) normal. HCG-stimulated testosterone/androstenedion...

Objective: Remission rates in young people with Graves’ hyperthyroidism are <25% after a 2-yr course of thionamide antithyroid drug (ATD). Immunomodulatory agents might improve outcome by facilitating immune tolerance. We explored whether rituximab (RTX) would increase remission rates when administered with a short course of ATD.Design: This was an open label multi-centre single arm phase 2 trial in newly presenting young people (12-20y) with Gr...